Dosing patterns and dose effects of sacubitril/valsartan: A claims-based retrospective cohort study.
<h4>Purpose</h4>The goals of this retrospective cohort analysis were to determine real-world dose and titration patterns of sacubitril/valsartan (SAC/VAL), a heart failure medication, and examine whether dose patterns are associated with healthcare utilization and costs.<h4>Methods...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2025-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0320216 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849736215356506112 |
|---|---|
| author | Jillian M Rung Tyson S Barrett Keith LeJeune Shannon B Richards Amresh Raina Lawrence Sinoway |
| author_facet | Jillian M Rung Tyson S Barrett Keith LeJeune Shannon B Richards Amresh Raina Lawrence Sinoway |
| author_sort | Jillian M Rung |
| collection | DOAJ |
| description | <h4>Purpose</h4>The goals of this retrospective cohort analysis were to determine real-world dose and titration patterns of sacubitril/valsartan (SAC/VAL), a heart failure medication, and examine whether dose patterns are associated with healthcare utilization and costs.<h4>Methods</h4>Adult health plan members (18-100 years old) who initiated SAC/VAL between 2020 and 2022 and had continuous enrollment 6 months prior to, and at least 3 months following SAC/VAL initiation were identified. Members also had to have 3 months of SAC/VAL fills with good adherence (N = 2,977). Claims data were used to characterize dosage patterns and compare total costs of care, as well as all-cause and heart failure- hospital admissions across those with different terminal SAC/VAL doses.<h4>Results</h4>Most members initiated SAC/VAL at the lowest dose (76%, n = 2,267), of whom few titrated upward by their final fill (31%, n = 703). Overall, only 19% (n = 563) were at target by their final fill. Those ending on higher doses experienced significantly fewer all-cause admissions (incidence rate ratios of 1.52 [SE = .16] to 2.66 [SE = .37]; ps < .001) and incurred significantly lower total costs of care while on SAC/VAL (cost ratios of 1.21 [SE = .06] to 1.48 [SE = .09]; ps < .001).<h4>Conclusion</h4>Most individuals initiate and remain on the lowest SAC/VAL dose despite guidelines to titrate upward. SAC/VAL dosage is significantly associated with outcomes, with higher doses associated with more clinical and cost benefits. Research is needed to identify barriers to dose titration and to develop interventions for maximal patient benefit. |
| format | Article |
| id | doaj-art-3f522e67eb8b431da647290f65663ad3 |
| institution | DOAJ |
| issn | 1932-6203 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-3f522e67eb8b431da647290f65663ad32025-08-20T03:07:20ZengPublic Library of Science (PLoS)PLoS ONE1932-62032025-01-01203e032021610.1371/journal.pone.0320216Dosing patterns and dose effects of sacubitril/valsartan: A claims-based retrospective cohort study.Jillian M RungTyson S BarrettKeith LeJeuneShannon B RichardsAmresh RainaLawrence Sinoway<h4>Purpose</h4>The goals of this retrospective cohort analysis were to determine real-world dose and titration patterns of sacubitril/valsartan (SAC/VAL), a heart failure medication, and examine whether dose patterns are associated with healthcare utilization and costs.<h4>Methods</h4>Adult health plan members (18-100 years old) who initiated SAC/VAL between 2020 and 2022 and had continuous enrollment 6 months prior to, and at least 3 months following SAC/VAL initiation were identified. Members also had to have 3 months of SAC/VAL fills with good adherence (N = 2,977). Claims data were used to characterize dosage patterns and compare total costs of care, as well as all-cause and heart failure- hospital admissions across those with different terminal SAC/VAL doses.<h4>Results</h4>Most members initiated SAC/VAL at the lowest dose (76%, n = 2,267), of whom few titrated upward by their final fill (31%, n = 703). Overall, only 19% (n = 563) were at target by their final fill. Those ending on higher doses experienced significantly fewer all-cause admissions (incidence rate ratios of 1.52 [SE = .16] to 2.66 [SE = .37]; ps < .001) and incurred significantly lower total costs of care while on SAC/VAL (cost ratios of 1.21 [SE = .06] to 1.48 [SE = .09]; ps < .001).<h4>Conclusion</h4>Most individuals initiate and remain on the lowest SAC/VAL dose despite guidelines to titrate upward. SAC/VAL dosage is significantly associated with outcomes, with higher doses associated with more clinical and cost benefits. Research is needed to identify barriers to dose titration and to develop interventions for maximal patient benefit.https://doi.org/10.1371/journal.pone.0320216 |
| spellingShingle | Jillian M Rung Tyson S Barrett Keith LeJeune Shannon B Richards Amresh Raina Lawrence Sinoway Dosing patterns and dose effects of sacubitril/valsartan: A claims-based retrospective cohort study. PLoS ONE |
| title | Dosing patterns and dose effects of sacubitril/valsartan: A claims-based retrospective cohort study. |
| title_full | Dosing patterns and dose effects of sacubitril/valsartan: A claims-based retrospective cohort study. |
| title_fullStr | Dosing patterns and dose effects of sacubitril/valsartan: A claims-based retrospective cohort study. |
| title_full_unstemmed | Dosing patterns and dose effects of sacubitril/valsartan: A claims-based retrospective cohort study. |
| title_short | Dosing patterns and dose effects of sacubitril/valsartan: A claims-based retrospective cohort study. |
| title_sort | dosing patterns and dose effects of sacubitril valsartan a claims based retrospective cohort study |
| url | https://doi.org/10.1371/journal.pone.0320216 |
| work_keys_str_mv | AT jillianmrung dosingpatternsanddoseeffectsofsacubitrilvalsartanaclaimsbasedretrospectivecohortstudy AT tysonsbarrett dosingpatternsanddoseeffectsofsacubitrilvalsartanaclaimsbasedretrospectivecohortstudy AT keithlejeune dosingpatternsanddoseeffectsofsacubitrilvalsartanaclaimsbasedretrospectivecohortstudy AT shannonbrichards dosingpatternsanddoseeffectsofsacubitrilvalsartanaclaimsbasedretrospectivecohortstudy AT amreshraina dosingpatternsanddoseeffectsofsacubitrilvalsartanaclaimsbasedretrospectivecohortstudy AT lawrencesinoway dosingpatternsanddoseeffectsofsacubitrilvalsartanaclaimsbasedretrospectivecohortstudy |